References

• 1. Tharanathan RN, Kittur FS. Chitin-the undisputed biomolecule of great potential. Crit Rev Food Sci Nutr 2003; 43(1): 61-87. google scholar
• 2. Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Mar Biotechnol (NY) 2006; 8(3): 203-26. google scholar
• 3. White SA, Farina PR, Fulton I. Production and isolation of chitosan from Mucor rouxii. Appl Environ Microbiol 1979; 38(2): 323-8. google scholar
• 4. Elieh-Ali-Komi D, Hamblin MR. Chitin and chitosan: Production and application of versatile biomedical nanomaterials. Int J Adv Res (Indore) 2016; 4(3): 411-27. google scholar
• 5. Synowiecki J, Al-Khateeb NA. Production, properties, and some new applications of chitin and its derivatives. Crit Rev Food Sci Nutr 2003; 43(2): 145-71. google scholar
• 6. Felt O, Baeyens V, Buri P, Gurny R. Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle. AAPS PharmSci 2001; 3(4): E34. google scholar
• 7. Turan K, Nagata K. Chitosan-DNA nanoparticles: the effect of cell type and hydrolysis of chitosan on in vitro DNA transfection. Pharm Dev Technol 2006; 11(4): 503-12. google scholar
• 8. Dastan T, Turan K. In vitro characterization and delivery of chitosan-DNA microparticles into mammalian cells. J Pharm Pharm Sci 2004; 7(2): 205-14. google scholar
• 9. Muanprasat C, Chatsudthipong V. Chitosan oligosaccharide: Biological activities and potential therapeutic applications. Pharmacol Ther 2017; 170: 80-97. google scholar
• 10. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001; 52(2):145-50. google scholar
• 11. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 2001; 14(3): 201-7. google scholar
• 12. Muzzarelli RA. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs 2010; 8(2): 292-312. google scholar
• 13. Porporatto C, Bianco ID, Correa SG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol 2005; 78(1): 62-9. google scholar
• 14. Li D, Fu D, Kang H, Rong G, Jin Z, Wang X, et al. Advances and Potential Applications of Chitosan Nanoparticles as a Delivery Carrier for the Mucosal Immunity of Vaccine. Curr Drug Deliv 2017; 14(1): 27-35. google scholar
• 15. Elderfield R, Barclay W. Influenza pandemics. Adv Exp Med Biol 2011; 719: 81-103. google scholar
• 16. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006; 12(1): 9-14. google scholar
• 17. Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am 2004; 18(1): 141-55. google scholar
• 18. Robertson JS, Inglis SC. Prospects for controlling future pandemics of influenza. Virus Res 2011; 162(1-2): 39-46. google scholar
• 19. Marcelin G, Sandbulte MR, Webby RJ. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 2012; 22(4): 267-79. google scholar
• 20. Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS Pharm Sci Tech 2014; 15(2): 317-25. google scholar
• 21. Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol 2011; 40: 20-35. google scholar
• 22. Shakya AK, Chowdhury MYE, Tao W, Gill HS. Mucosal vaccine delivery: Current state and a pediatric perspective. J Control Release 2016; 240: 394-413. google scholar
• 23. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Milani MA, Jelvehgari M. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery. Arch Pharm Res. 2016; 39(9): 1181-92. google scholar
• 24. Doavi T, Mousavi SL, Kamali M, Amani J, Fasihi Ramandi M. Chitosan-Based Intranasal Vaccine against Escherichia coli O157:H7. Iran Biomed J 2016; 20(2): 97-108. google scholar
• 25. Rauw F, Gardin Y, Palya V, Anbari S, Gonze M, Lemaire S, et al. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet Immunol Immunopathol 2010; 134(3-4): 249-58. google scholar
• 26. Volkova MA, Irza AV, Chvala IA, Frolov SF, Drygin VV, Kapczynski DR. Adjuvant effects of chitosan and calcium phosphate particles in an inactivated Newcastle disease vaccine. Avian Dis 2014; 58(1): 46-52. google scholar
• 27. Vasiliev YM. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Rev Vaccines 2015; 14: 37-53. google scholar
• 28. Sonaje K, Chuang EY, Lin KJ, Yen TC, Su FY, Tseng MT, et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012; 9(5): 1271-9. google scholar
• 29. Sonaje K, Lin KJ, Tseng MT, Wey SP, Su FY, Chuang EY. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011; 32(33): 8712-21. google scholar
• 30. Barrett T, Inglis SC. Growth, purification and titration of influenza viruses. Ed. Mahy BWJ: Virology: A practical approach. Oxford, IRL Press, 1985; pp 119-50. google scholar
• 31. Chrystie IL. Electron Mycroscopy. Eds. Mahy BWJ, Kangro HO. Virology methods manual. London: Academic Press, 1996; pp 91-107. google scholar
• 32. Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. Eds. In Nunnally BK, Turula VE, Sitrin RD. Vaccine Analysis: Strategies, Principles, and Control. Berlin Heidelberg: Springer-Verlag Berlin Heidelberg, 2015; pp 45-79. google scholar
• 33. Shu XZ, Zhu KJ. Chitosan/gelatin microspheres prepared by modified emulsification and ionotropic gelation. J Microencapsul 2001; 18(2): 237-45. google scholar
• 34. Lim ST, Martin GP, Berry DJ, Brown MB. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J Control Release 2000; 66(2-3): 281-92. google scholar
• 35. Mi FL, Shyu SS, Chen CT, Schoung JY. Porous chitosan microsphere for controlling the antigen release of Newcastle disease vaccine: preparation of antigen-adsorbed microsphere and in vitro release. Biomaterials 1999; 20(17): 1603-12. google scholar
• 36. Global Health Estimates Technical Paper: Mathers C, Stevens G, Mahanani WR, et al.. WHO methods and data sources for country‐level causes of death 2000‐2015. 2017. WHO/HIS/IER/GHE/2016.3. google scholar
• 37. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected? Emerg Microbes Infect 2012; 1(12): e46. google scholar
• 38. Kaur L, Sharma A, Yadav AK, Mishra N. Recent advances on biodegradable polymeric carrier-based mucosal immunization: an overview. Artif Cells Nanomed Biotechnol 2018; 46(3): 452-64. google scholar
• 39. MuZikova G, Laga R. Macromolecular systems for vaccine delivery. Physiol Res 2016; 65:S203-S216. google scholar
• 40. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology 2011; 9: 55. google scholar
• 41. Arthanari S, Mani G, Peng MM, Jang HT. Chitosan-HPMC-blended microspheres as a vaccine carrier for the delivery of tetanus toxoid. Artif Cells Nanomed Biotechnol 2016; 44(2): 517-23. google scholar
• 42. Ali A, Ahmed S. A review on chitosan and its nanocomposites in drug delivery. Int J Biol Macromol 2018; 109: 273-86. google scholar
• 43. Mitra A, Dey B. Chitosan microspheres in novel drug delivery systems. Indian J Pharm Sci 2011; 73(4): 355-66. google scholar
• 44. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996; 189 (Pt 3): 503-5. google scholar
• 45. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 2005; 292(1): 43-52. google scholar
• 46. Oliveira CR, Rezende CM, Silva MR, Pêgo AP, Borges O, Goes AM. A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis. PLoS Negl Trop Dis 2012; 6(11): e1894. google scholar
• 47. Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm 2013; 2013: 848043. google scholar
• 48. Ito Y, Kusawake T, Ishida M, Tawa R, Shibata N, Takada K. Oral solid gentamicin preparation using emulsifier and adsorbent. J Control Release 2005; 105(1-2): 23-31. google scholar
• 49. Gupta KC, Ravi Kumar MN. Drug release behavior of beads and microgranules of chitosan. Biomaterials 2000; 21(11): 1115-9. google scholar
• 50. Orienti I, Aiedeh K, Gianasi E, Bertasi V, Zecchi V. Indomethacin loaded chitosan microspheres. Correlation between the erosion process and release kinetics. J Microencapsul 1996; 13(4): 463-72. google scholar
• 51. Kas HS. Chitosan: properties, preparations and application to microparticulate systems. J Microencapsul 1997; 14(6): 689-711. google scholar
• 52. Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012; 33(19): 495764. google scholar

Citations